Nexus Pharmaceuticals announces launch of new injection
Lincolnshire-based Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL multiple-dose vials. It is an AP-rated generic to Quelicin.
"The launch of Succinylcholine Chloride represents Nexus Pharmaceuticals' ability to supply critical products and to help fortify the supply chain," said Shahid Ahmed, Chief Scientific Officer of Nexus Pharmaceuticals.
"The COVID-19 pandemic deeply disrupted the supply of Succinylcholine Chloride, but Nexus' entry into the market will help alleviate constraints and provide peace of mind for our clinical partners."
Nexus Pharmaceuticals' Succinylcholine Chloride Injection is available in cartons of 25 vials.
Succinylcholine Chloride Injection, USP is a sterile, nonpyrogenic solution to be used as an ultra-short-acting, depolarizing, skeletal muscle relaxant. Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.